COLOPLAST A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 818.2 DKK | +1.39% |
|
-2.87% | +5.98% |
| May. 15 | COLOPLAST : Multiple silver linings in spite of a soft Q2 24 |  |
| May. 07 | European shares hit one-month high as earnings take centre stage | RE |
| Sales 2024 * | 27.04B 3.94B | Sales 2025 * | 29.38B 4.29B | Capitalization | 184B 26.83B |
|---|---|---|---|---|---|
| Net income 2024 * | 5.25B 766M | Net income 2025 * | 6.12B 893M | EV / Sales 2024 * | 7.52 x |
| Net Debt 2024 * | 19.4B 2.83B | Net Debt 2025 * | 18.06B 2.63B | EV / Sales 2025 * | 6.88 x |
| P/E ratio 2024 * |
35.2
x | P/E ratio 2025 * |
30.1
x | Employees | 15,930 |
| Yield 2024 * |
2.46% | Yield 2025 * |
2.69% | Free-Float | 58.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on Coloplast A/S
More press releases
| 1 day | +1.39% | ||
| 1 week | -4.77% | ||
| Current month | -0.80% | ||
| 1 month | -4.86% | ||
| 3 months | -10.77% | ||
| 6 months | +3.75% | ||
| Current year | +5.98% |
1 week
802.20
838.80
1 month
802.20881.00
Current year
757.80977.60
1 year
689.20977.60
3 years
689.201 194.00
5 years
689.201 194.00
10 years
413.101 194.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 07-12-31 | |
| Director of Finance/CFO | 52 | 05-12-31 | |
| Chairman | 65 | 87-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 76 | 68-09-30 | |
Carsten Hellmann
BRD | Director/Board Member | 60 | 17-11-30 |
| Chairman | 65 | 87-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.81% | 200 M€ | +16.29% | ||
| 1.11% | 253 M€ | +6.60% | ||
| 0.96% | 48 M€ | +9.33% | ||
| 0.85% | 3 M€ | +9.95% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-04 | 818.2 | +1.39% | 179,324 |
| 24-06-03 | 807 | -2.16% | 352,143 |
| 24-05-31 | 824.8 | -0.31% | 1,276,697 |
| 24-05-30 | 827.4 | +0.66% | 293,451 |
| 24-05-29 | 822 | -2.42% | 296,060 |
Delayed Quote Nasdaq Copenhagen, June 04, 2024 at 10:59 am EDT
More quotes
Coloplast A/S specializes in the design, manufacturing, and marketing of disposable medical products. Net sales break down by family of products as follows:
- hygiene products (43.4%): urine bags, plugs, urinary testing systems and sets, etc.;
- ostomy care products (36.8%): bags and equipment used following intestinal operations;
- wound care and skincare products (11.9%): wound dressings, bandages, creams and gels;
- voice and respiratory care products (7.9%): voice prostheses for speaking, adhesives, laryngectomy cannulas for breathing, hands-free speaking devices, etc.
Net sales are distributed geographically as follows: Denmark (1.4%), the United States (21%), the United Kingdom (14%), France (10.8%) and other (52.8%).
Calendar
2024-06-06
- Investor Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
818.2
DKK
Average target price
909.9
DKK
Spread / Average Target
+11.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.98% | 26.49B | |
| -39.95% | 2.67B | |
| -21.34% | 2.37B | |
| +17.78% | 2.28B | |
| +9.63% | 2.27B | |
| -13.64% | 1.83B | |
| +15.56% | 1.79B | |
| +21.61% | 1.32B | |
| -3.29% | 1.27B | |
| +21.62% | 1.2B |
- Stock Market
- Equities
- COLO B Stock
